Exhibit 4.3


 


THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE BEEN AND WILL BE ISSUED WITHOUT REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED
WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY
SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE
OF SUCH SECURITIES IS MADE PURSUANT TO RULE 144 PROMULGATED UNDER THE ACT.


 


	 	 	Menlo Park, California
	 	 	 
	Date of Issuance: July 1, 2021	 	Void after: July 1, 2026


 


WARRANT TO PURCHASE COMMON STOCK


of


TIVIC HEALTH SYSTEMS, INC.


 


This Warrant to Purchase Common
Stock of Tivic Health Systems, Inc. (this “Warrant”), is issued to Hanover International, Inc. (and, together with
its permitted successors and assigns, the “Holder”) by Tivic Health Systems, Inc., a Delaware corporation (the “Company”).


 


1.                  
Purchase of Shares.


 


(a)              
Number of Shares. Subject to the terms and conditions set forth herein, the Holder is entitled,
upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the Holder in
writing), to purchase from the Company up to 200,000 fully paid and nonassessable shares of the Company’s Common Stock (the “Common
Stock”). 


 


(b)              
Exercise Price. The exercise price for the shares of Common Stock issuable pursuant to Section
1(a) of this Warrant (the “Shares”) shall be $0.26 per share (the “Exercise Price”). The Shares
and the Exercise Price shall be subject to adjustment pursuant to Section 8 hereof. 


 


2.                   Exercise
Period. This Warrant shall be exercisable beginning on the date of this Warrant and ending at 5:00 p.m. Pacific time on the
five-year anniversary of the date hereof (the “Exercise Period”); provided, however, that this Warrant
shall no longer be exercisable and become null and void upon the consummation of a Change of Control. In the event of a Change of
Control, the Company shall notify the Holder at least ten (10) days prior to the consummation of such Change of Control. For the
purposes hereof, a “Change of Control” shall mean (i) the direct or indirect sale or transfer, in a single
transaction or a series of related transactions, by the stockholders of the Company of voting securities, in which the holders of
the outstanding voting securities of the Company immediately prior to such transaction or series of transactions hold, as a result
of holding Company securities prior to such transaction, in the aggregate, securities possessing less than fifty percent (50%) of
the total combined voting power all outstanding voting securities of the Company or of the acquiring entity immediately after such
transaction or series of related transactions; (ii) a merger or consolidation in which the Company is not the surviving entity,
except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to such merger
or consolidation hold as a result of holding Company securities prior to such transaction, in the aggregate, securities possessing
more than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the surviving entity (or
the parent of the surviving entity) immediately after such merger or consolidation; (iii) a reverse merger in which the Company is
the surviving entity but in which the holders of the outstanding voting securities of the Company immediately prior to such merger
hold as a result of holding Company securities prior to such transaction, in the aggregate, securities possessing less than fifty
percent (50%) of the total combined voting power of all outstanding voting securities of the Company or of the acquiring entity
immediately after such merger; or (iv) the sale, transfer or other disposition (in one transaction or a series of related
transactions) of all or substantially all of the assets of the Company, except for a transaction in which the holders of the
outstanding voting securities of the Company immediately prior to such transaction(s) receive as a distribution with respect to
securities of the Company, in the aggregate, securities possessing more than fifty percent (50%) of the total combined voting power
of all outstanding voting securities of the acquiring entity immediately after such transaction(s). Notwithstanding the foregoing or
anything herein contained to the contrary, the following shall not be deemed to constitute a Change in Control: (A) a merger
effected exclusively for the purpose of changing the domicile of the Company; or (B) a transaction or series of related transactions
in which the stockholders of the Corporation immediately following such transaction or series of related transactions own 50% or
less of the voting power of the Corporation if such transactions were undertaken wholly or primarily for capital raising
purposes.


 






    1


     


    

 


3.                  
Method of Exercise.


 


(a)              
While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the Holder
may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by:


 


(i)                
the surrender of the Warrant, together with a duly executed copy of the Notice of Exercise attached
hereto, to the Secretary of the Company at its principal office (or at such other place as the Company shall notify the Holder in writing);
and


 


(ii)             
the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares
being purchased.


 


(b)              
Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close
of business on the day on which this Warrant is surrendered to the Company as provided in Section 3(a) above. At such time, the person
or persons in whose name or names any certificate for the Shares shall be issuable upon such exercise as provided in Section 3(c) below
shall be deemed to have become the holder or holders of record of the Shares represented by such certificate.


 


(c)              
As soon as practicable after the exercise of this Warrant in whole or in part, the Company at its
expense will cause to be issued in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable
transfer taxes) may direct:


 


(i)                
a certificate or certificates for the number of Shares to which such Holder shall be entitled, and



 


(ii)             
in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like
tenor, calling in the aggregate on the face or faces thereof for the number of Shares equal to the number of such Shares described in
this Warrant minus the number of such Shares purchased by the Holder upon all exercises made in accordance with Section 3(a) above.


 






    2


     


    

 


4.                  
Reserved.


 


5.                  
 Warranties and Covenants of the Company. 


 


(a)              
In connection with the transactions provided for herein, the Company hereby represents and warrants
to the Holder that the Shares, when issued, sold, and delivered in accordance with the terms of the Warrants for the consideration expressed
therein, will be (i) duly and validly issued, fully paid and nonassessable, (ii) free from all taxes, liens and charges with respect to
the issuance thereof, and (iii) based in part upon the representations and warranties of the Holders in this Warrant, will be issued in
compliance with all applicable federal and state securities laws.


 


(b)              
The Company covenants and agrees that the Company will at all times during the Exercise Period, have
authorized and reserved, free from preemptive rights, a sufficient number of shares of its Common Stock to provide for the exercise of
the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of the
Company’s Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as
may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares
as shall be sufficient for such purposes.


 


(c)              
In the event of any taking by the Company of a record of the holders of any class of securities for
the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, the Company shall mail
to the Holder, at least 10 days prior to the date of such record, a notice specifying the date on which such record is to be taken for
the purpose of such dividend or distribution.


 


6.                  
Representations and Warranties of the Holder. In connection with the transactions provided for herein, the Holder hereby
represents and warrants to the Company that:


 


(a)              
Authorization. Holder represents that it has full power and authority to enter into this Warrant.
This Warrant constitutes the Holder’s valid and legally binding obligation, enforceable in accordance with its terms, except as
may be limited by (i) applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors’
rights and (ii) laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 


 


(b)              
Purchase Entirely for Own Account. The Holder acknowledges that this Warrant is entered into
by the Holder in reliance upon such Holder’s representation to the Company that the Warrant and the Shares (collectively, the “Securities”)
will be acquired for investment for the Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution
of any part thereof, and that the Holder has no present intention of selling, granting any participation in or otherwise distributing
the same. By acknowledging this Warrant, the Holder further represents that the Holder does not have any contract, undertaking, agreement,
or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Securities.



 


(c)              
Disclosure of Information. The Holder acknowledges that it has received all the information
it considers necessary or appropriate for deciding whether to acquire the Securities. The Holder further represents that it has had an
opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities.


 


(d)              
Investment Experience. The Holder acknowledges that it is able to fend for itself, can bear
the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating
the merits and risks of the investment in the Securities. If other than an individual, the Holder also represents it has not been organized
solely for the purpose of acquiring the Securities.


 






    3


     


    

 


(e)              
 Accredited Investor. The Holder is an “accredited investor” within the meaning
of Rule 501 of Regulation D, as presently in effect, as promulgated by the Securities and Exchange Commission (the “SEC”)
under the Act.


 


(f)               
Restricted Securities. The Holder understands that the Securities are characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving
a public offering and that under such laws and applicable regulations such securities may be resold without registration under the Act,
only in certain limited circumstances. In this connection, each Holder represents that it is familiar with Rule 144, as presently in effect,
as promulgated by the SEC under the Act (“Rule 144”), and understands the resale limitations imposed thereby and by
the Act.


 


(g)              
Further Limitations on Disposition. Without in any way limiting the representations set forth
above, the Holder further agrees not to make any disposition of all or any portion of the Shares unless and until the transferee has agreed
in writing for the benefit of the Company to be bound by the terms of this Warrant, including, without limitation, this Section 6, Section
19, and any right of first refusal as may be set forth in the Bylaws of the Company, and:


 


(i)                
there is then in effect a registration statement under the Act covering such proposed disposition
and such disposition is made in accordance with such registration statement; or


 


(ii)             
the Holder shall have notified the Company of the proposed disposition and shall have furnished the
Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company,
the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition
will not require registration of such shares under the Act. It is agreed that the Company will not require opinions of counsel for transactions
made pursuant to Rule 144 except in extraordinary circumstances.


 


(h)              
Legends. It is understood that the Securities may bear the following legend, or substantially
similar legends: 


 


(i)             
“THE SECURITIES REPRESENTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION
UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO
THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES
IS MADE PURSUANT TO RULE 144 PROMULGATED UNDER THE ACT.”


 


(ii)          
“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION
IN FAVOR OF THE CORPORATION AND CERTAIN STOCKHOLDERS OF THE CORPORATION, AS PROVIDED IN THE BYLAWS OF THE CORPORATION, A COPY OF WHICH
IS ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION AND THE SALE, TRANSFER OR HYPOTHECATION OF SUCH SHARES MAY NOT BE EFFECTED OTHER
THAN IN ACCORDANCE WITH THE PROVISIONS THEREOF.”


 


7.                   State
Commissioners of Corporations. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF
THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM
QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.


 






    4


     


    

 


8.                  
Adjustment of Exercise Price and Number of Shares. The number and kind of Shares purchasable upon exercise of this Warrant
and the Exercise Price shall be subject to adjustment from time to time as follows:


 


(a)              
Subdivisions, Combinations and Other Issuances. If the Company shall at any time after the
issuance but prior to the expiration of this Warrant subdivide its Common Stock, by split-up or otherwise, or combine its Common Stock,
or issue additional shares of its Common Stock or Common Stock as a dividend with respect to any shares of its Common Stock, the number
of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock
dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise Price
payable per share, but the aggregate Exercise Price payable for the total number of Shares purchasable under this Warrant (as adjusted)
shall remain the same. Any adjustment under this Section 8(a) shall become effective at the close of business on the date the subdivision
or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making
of such dividend.


 


(b)              
Reclassification, Reorganization and Consolidation. In case of any reclassification, capital
reorganization or change in the capital stock of the Company (other than as a result of a subdivision, combination or stock dividend provided
for in Section 8(a) above), then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and
duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall
have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise
of this Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Shares by the Holder immediately
prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to the rights
and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities
or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price per Share payable hereunder,
provided the aggregate Exercise Price shall remain the same.


 


(c)              
Notice of Adjustment. When any adjustment is required to be made in the number or kind of
shares purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall notify the Holder of such event and of the
number of Shares or other securities or property thereafter purchasable upon exercise of this Warrant.


 


(d)              
Conversion of Common Stock. In the event that all outstanding shares of Common Stock are converted
to any other security, this Warrant shall become exercisable for such other security.


 


9.                  
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price
then in effect.


 


10.               No
Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder with
respect to the Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions
thereon, exercise preemptive rights or be notified of stockholder meetings, and, except as otherwise provided in this Warrant, such
Holder shall not be entitled to any stockholder notice or other communication concerning the business or affairs of the Company.


 






    5


     


    

 


11.              
Governing Law; Venue. This Warrant shall be governed by and construed under the laws of the State of California as applied
to agreements among California residents, made and to be performed entirely within the State of California. The parties agree that any
dispute arising in connection with the interpretation or validity of, or otherwise arising out of, this Warrant, will be subject to the
exclusive jurisdiction of the California State and Federal Courts in and for Santa Clara County, California. The parties hereby agree
to submit to the personal and exclusive jurisdiction and venue of such courts and agree that process may be served in the manner provided
herein for the giving of notices or otherwise as allowed by applicable law. Each party hereto waives any defense of inconvenient forum
to the maintenance of any action so brought and waives any bond, surety, or other security that might be required of any other party with
respect thereto.


 


12.              
Successors and Assigns. The terms and provisions of this Warrant and the Purchase Agreement shall inure to the benefit of,
and be binding upon, the Company and the holders hereof and their respective successors and permitted assigns.


 


13.              
Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered
in construing or interpreting this Warrant.


 


14.              
Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail if sent during normal business
hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered
or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the respective parties
at addresses set forth on the signature pages hereto (or at such other addresses as shall be specified by notice given in accordance with
this Section 14).


 


15.              
Expenses. If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing
party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which
such party may be entitled.


 


16.              
Entire Agreement; Amendments and Waivers. This Warrant and any other documents delivered pursuant hereto constitute the
full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. Nonetheless, any term
of this Warrant may be amended and the observance of any term of this Warrant may be waived (either generally or in a particular instance
and either retroactively or prospectively), with the written consent of the Company and the Holder; or if this Warrant has been assigned
in part, by the holders or rights to purchase a majority of the shares originally issuable pursuant to this Warrant.


 


17.              
Loss or Mutilation. Upon receipt of evidence reasonably satisfactory to the Company of the ownership of and the loss, theft,
destruction or mutilation of this Warrant, and of indemnity reasonably satisfactory to it, and (in the case of mutilation) upon surrender
and cancellation of this Warrant, the Company will execute and deliver in lieu thereof a new Warrant of like tenor as the lost, stolen,
destroyed or mutilated Warrant.


 






    6


     


    

 


18.              
 Severability. If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be
excluded from this Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.


 


19.              
“Market Stand-Off” Agreement. In connection with the Initial Public Offering, each Investor or a transferee
thereof, shall not, directly or indirectly, sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any option or
other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree
to engage in any of the foregoing transactions with respect to, any capital stock acquired through the exercise of this Warrant without
the prior written consent of the Company or its managing underwriter. Such restriction (the “Market Stand-Off”) shall
be in effect for such period of time following the date of the final prospectus for the offering as may be requested by the Company or
such underwriter. In no event, however, shall such period exceed one hundred eighty (180) days plus such additional period as may reasonably
be requested by the Company or such underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of
research reports, or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in FINRA Rule
2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), or any similar successor rules. In the event of
the declaration of a stock dividend, a spin off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction
affecting the Company’s outstanding securities without receipt of consideration, any new, substituted or additional securities which
are by reason of such transaction distributed with respect to any capital stock acquired through the exercise of this Warrant subject
to the Market Stand-Off, or into which such capital stock acquired through the exercise of this Warrant thereby become convertible, shall
immediately be subject to the Market Stand-Off. The Company’s underwriters shall be beneficiaries of the agreement set forth in
this Section 19. This Section 19 shall not apply to securities registered in the public offering under the Act or to any securities issued
by the Company that are purchased by Investors on the open market. All certificates evidencing capital stock acquired through the exercise
of this Warrant (and any securities issued in substitution thereof or in respect thereof) shall bear such restrictive legends as the Company
and the Company’s counsel deem necessary or advisable under applicable law or pursuant to this Warrant, including, without limitation,
the following:


 


THE SECURITIES REPRESENTED HEREBY ARE SUBJECT
TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF UP TO 180 DAYS FOLLOWING THE EFFECTIVE DATE OF A REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, FOR AN OFFERING OF THE COMPANY’S SECURITIES PURSUANT TO THE MARKET STANDOFF PROVISIONS OF AN AGREEMENT
BETWEEN THE COMPANY AND THE ORIGINAL PURCHASER OF SUCH SECURITIES, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.


 


[Remainder
of page intentionally left blank]


 






    7


     


    

 


IN WITNESS WHEREOF, the parties
have executed this Warrant as of the date first written above.


 


	 	TIVIC
    HEALTH SYSTEMS, INC.
	 	 
	 	By: 	/s/ Jennifer Ernst
	 	Jennifer
    Ernst, Chief Executive Officer
	 	 
	 	Address:
    750 Menlo Ave. Suite 200
	 	Menlo
    Park, California 94025
	 	Attn:
    Chief Executive Officer
	 	Email
    Address: jennifer.ernst@tivichealth.com




 


ACKNOWLEDGED AND AGREED:


 


	Hanover
    International, Inc.	 
	 	 
	By:	/s/
    James Hock	 
	Name: 	James
    Hock	 
	Title:	President	 




 


	Address:	 	 
	 	 	 







 


	Email:	 	 




 






    8


     


    

 


NOTICE
OF EXERCISE


 


TIVIC HEALTH SYSTEMS, INC.


Attention: Corporate Secretary


 


The undersigned hereby elects
to purchase, pursuant to the provisions of the Warrant, as follows:


 


		 ̈	_____________ shares of Common Stock pursuant to the terms of the attached Warrant, and tenders herewith
payment in cash of the Exercise Price of such Shares in full, together with all applicable transfer taxes, if any.



 


The undersigned hereby represents
and warrants that Representations and Warranties in Section 6 hereof are true and correct as of the date hereof.


 


	 	HOLDER:
	 	 
	Date:	 	 	By:	 




 


	 	Address:	 
	 	 
	 	 




 


Name in which shares should be registered:


 


	 	 	 




 






    9